Hoyoung Huh, M.D., Ph.D.
Chairman of the Board and Nominating and Corporate Governance Committee
Hoyoung Huh, M.D., Ph.D., has been the Chairman of the Board since September 2011, served as our interim Executive Chairman from February 2011 to September 2011, and has served as a director of Geron since May 2010. He is also Chairman of the board of directors of Cytomx Therapeutics, Inc. and a director of AntriaBio, Inc. Additionally, Dr. Huh serves on the boards of directors of several privately-held companies. From May 2011 to May 2014, Dr. Huh served as a director of ADDEX Pharmaceuticals. From February 2008 to December 2011, Dr. Huh was Chairman of the board of directors of BiPar Sciences, Inc. since the April 2009 merger of BiPar and Sanofi-Aventis, and served as BiPar's President and Chief Executive Officer from February 2008 to December 2009. From September 2009 to April 2010, Dr. Huh served on the board of directors of Facet Biotech. From February 2008 to May 2009, he was a member of the board of directors at Nektar Therapeutics. From March 2005 to February 2008, Dr. Huh served as Nektar's Chief Operating Officer and Senior Vice President of Business Development and Marketing where he was responsible for the company's worldwide business development, marketing and manufacturing and led Nektar's PEGylation business. Prior to Nektar, Dr. Huh was a partner at McKinsey & Company where he served the biotechnology and biopharmaceutical sectors. Prior to McKinsey, he held positions as a physician and researcher at Cornell University Medical College and Sloan-Kettering Cancer Center. Dr. Huh holds an A.B. in biochemistry from Dartmouth College and an M.D. and Ph.D. in genetics and cell biology from Cornell University Medical College and Sloan-Kettering Institute.
Daniel M. Bradbury
Audit Committee and Nominating and Corporate Governance Committee
Daniel M. Bradbury has served as a director of Geron since September 2012. He also serves as a member of the boards of directors of Illumina, Inc., Corcept Therapeutics, BioCon Ltd, and Syngene International, Ltd., as well as being a member of the board of trustees of the Keck Graduate Institute. Mr. Bradbury also serves on the University of California San Diego, Rady School of Management's Advisory Council, Investor Growth Capital Advisory Board and the BioMed Ventures Advisory Committee. He also served on the board of directors of BioMed Realty Trust, Inc. from January 2013 to January 2016. Mr. Bradbury served as Chief Executive Officer of Amylin Pharmaceuticals, Inc., from March 2007 until its acquisition by Bristol-Myers Squibb Company in August 2012. Mr. Bradbury served as Amylin's President from June 2006 until March 2007, as Chief Operating Officer from June 2003 until June 2006, as Executive Vice President from June 2000 until June 2003 and in other positions in corporate development and marketing from 1994 until 2000. In addition, Mr. Bradbury served as a member of the board of directors of Amylin from June 2006 until August 2012. Prior to joining Amylin, he spent ten years at SmithKline Beecham Pharmaceuticals, holding a number of sales and marketing positions. He received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom.
Audit Committee (Chair) and Compensation Committee
Karin Eastham has served as a director of Geron since March 2009. Ms. Eastham also serves as a director for MorphoSys AG, Illumina, Inc. and Veracyte, Inc. Ms. Eastham also served as a director of Trius Therapeutics, Inc. from 2009 until its sale in 2013; Amylin Pharmaceuticals, Inc. from 2005 until its sale in 2012; Genoptix, Inc. from 2008 until its sale in 2011; Tercica, Inc. from 2003 until its sale in 2008; and SGX Pharmaceuticals, Inc. from 2005 until its sale in 2008. From May 2004 to September 2008, she served as Executive Vice President and Chief Operating Officer, and as a member of the Board of Trustees, of Burnham Institute for Medical Research. From 1999 to 2004, Ms. Eastham served as Senior Vice President, Finance, Chief Financial Officer and Secretary of Diversa Corporation. She previously held similar positions with CombiChem, Inc. and Cytel Corporation. Ms. Eastham also held several positions, including Vice President, Finance, at Boehringer Mannheim Corporation from 1976 to 1988. Ms. Eastham holds a B.S. and an M.B.A. from Indiana University and is a Certified Public Accountant.
V. Bryan Lawlis, Ph.D.
Audit Committee and Compensation Committee
V. Bryan Lawlis, Ph.D., has served as a director of Geron since March 2012. He currently serves as a director for BioMarin Pharmaceuticals, Inc., Coherus Biosciences, Inc. and several privately-held biotechnology companies. From August 2013 to September 2014, Dr. Lawlis served as a director for KaloBios Pharmaceuticals, Inc. Dr. Lawlis is the President and Chief Executive Officer of Itero Biopharmaceuticals LLC that he co-founded in 2006. Dr. Lawlis served as President and Chief Executive Officer of Aradigm Corporation from August 2004, and served on its board of directors from February 2005, continuing in both capacities until August 2006. Dr. Lawlis served as Aradigm Corporation's President and Chief Operating Officer from June 2003 to August 2004 and its Chief Operating Officer from November 2001 to June 2003. Previously, Dr. Lawlis co-founded Covance Biotechnology Services, served as its President and Chief Executive Officer from 1996 to 1999, and served as Chairman from 1999 to 2001, when it was sold to Diosynth RTP, Inc. From 1981 to 1996, Dr. Lawlis was employed at Genencor, Inc. and Genentech, Inc. His last position at Genentech was Vice President of Process Sciences. Dr. Lawlis holds a B.A. in microbiology from the University of Texas at Austin and a Ph.D. in biochemistry from Washington State University.
Susan M. Molineaux, Ph.D.
Nominating and Corporate Governance Committee (Chair)
Susan M. Molineaux, Ph.D., has served as a director of Geron since September 2012. She is Chief Executive Officer and President of Calithera Biosciences, Inc. since co-founding the company in June 2010. She also serves as a member of the board of directors of Theravance Biopharma, Inc., as well as the Chairman of Bay Bio, Northern California's Life Science Association, and as a member of the board of directors of We Teach Science. Prior to Calithera, Dr. Molineaux co-founded Proteolix, Inc., where she served as Chief Scientific Officer from December 2003 until December 2005 and from February 2009 until November 2009, and as President and Chief Executive Officer from January 2006 until February 2009. Dr. Molineaux was responsible for leading the development of Proteolix's second-generation proteasome inhibitor, carfilzomib (now marketed as Kyprolis), for the treatment of multiple myeloma, from discovery through completion of clinical trials for accelerated approval, until the company's acquisition by Onyx Pharmaceuticals, Inc., in November 2009. From 2000 to 2003, Dr. Molineaux served as Vice President of Biology at Rigel Pharmaceuticals, Inc. She served as Vice President of Biology at Praelux, Inc. from 1999 to 2000, and from 1994 through 1999, as Vice President of Drug Development at Praecis Pharmaceuticals, Inc. From 1989 until 1994, she was a scientist in the Immunology group at Merck & Co. Dr. Molineaux holds a B.S. in biology from Smith College and a Ph.D. in molecular biology from Johns Hopkins University, and completed a postdoctoral fellowship at Columbia University.
John A. Scarlett, M.D.
President and Chief Executive Officer
John A. Scarlett, M.D., has served as our Chief Executive Officer and a director since September 2011 and President since January 2012. Dr. Scarlett also serves as a member of the board of directors of Chiasma, Inc. and CytomX Therapeutics, Inc. Prior to joining Geron, Dr. Scarlett served as President, Chief Executive Officer and a member of the board of directors of Proteolix, Inc. from February 2009 until its acquisition by Onyx Pharmaceuticals, Inc, in November 2009. From February 2002 until its acquisition by Ipsen, S.A. in October 2008, Dr. Scarlett served as the Chief Executive Officer and a member of the board of directors of Tercica, Inc. and also as its President from February 2002 through February 2007. From March 1993 to May 2001, Dr. Scarlett served as President and Chief Executive Officer of Sensus Drug Development Corporation. In 1995, he co-founded Covance Biotechnology Services, Inc., and served as a member of its board of directors from inception to 2000. From 1991 to 1993, Dr. Scarlett headed the North American Clinical Development Center and served as Senior Vice President of Medical and Scientific Affairs at Novo Nordisk Pharmaceuticals, Inc. Dr. Scarlett holds a B.A. in chemistry from Earlham College and an M.D. from the University of Chicago, Pritzker School of Medicine.
Robert J. Spiegel, M.D.
Compensation Committee (Chair)
Robert J. Spiegel, M.D., FACP, has served as a director of Geron since May 2010. He also serves as a member of the boards of directors of Edge Therapeutics, Inc., Sucampo Pharmaceuticals, Inc., and Avior Computing Corporation. He also is an Associate Fellow at the University of Pennsylvania Center for Bioethics and an Associate Professor at the Weill Cornell Medical School. From May 2011 to April 2016, Dr. Spiegel served as Chief Medical Officer of PTC Therapeutics, Inc. From 1995 to 2011, he served as a director of Cancer Care New Jersey and a director for the Cancer Institute of New Jersey from 1999 to 2009. After 26 years with the Schering-Plough Corporation (now Merck & Co.), Dr. Spiegel retired in 2009 as Chief Medical Officer and Senior Vice President of the Schering-Plough Research Institute. He initially joined Schering-Plough as Director of clinical research for oncology and rose to hold various positions including Vice President of clinical research and Senior Vice President of worldwide clinical research. As Senior Vice President of worldwide clinical research, Dr. Spiegel managed Phase 1 to Phase 3 clinical development in all therapy areas, including allergy, respiratory, cardiovascular, immunology, dermatology, oncology and infectious diseases. As Chief Medical Officer, Dr. Spiegel was involved with over 30 New Drug Applications, participated in multiple due diligence reviews and in-licensing decisions, re-engineered pharmacovigilence and risk management areas and built a quality system for all research operations. Following a residency in internal medicine, Dr. Spiegel completed a fellowship in medical oncology at the National Cancer Institute, and from 1981 to 1999 he held academic positions at the National Cancer Institute and New York University Cancer Center. Dr. Spiegel holds a B.A. from Yale University and an M.D. from the University of Pennsylvania.